Progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy
“The encouraging start to the year with organic growth of 9% and progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy, differentiating us as a bioscience company focused on microbial and fermentation technology platforms. Food Cultures &a
Chr. Hansen has launched its next-generation SWEETY® culture, the latest addition to its sugar reduction portfolio for fresh dairy.
Med sigte på at opnå en lav-emissionsfremtid udgør Chr. Hansens Science Based Targets kernen i virksomhedens strategi om at reducere sit klimaaftryk frem mod 2030. Med sit nye klimaprogram ’Think Climate. Naturally.’ vil bioscience-lederen afkoble sin klimapåvirkning fra virksomhedens økonomiske vækst.
Chr. Hansen lancerer i dag to science-based klimamål, der danner grundlag for virksomhedens s
Pursuing a low-carbon future, Chr. Hansen’s Science Based Targets form the core of the company’s strategy to reduce its carbon footprint towards 2030. Under its newly launched program; Think Climate. Naturally., the bioscience leader now sets out to decouple its climate impact from economic growth.
Chr. Hansen today announced two science-based climate targets that will form the basis of the com
SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen.
Basel, Switzerland and Hørsholm, Denmark, 10 November 2021 – Bacthera, a specialized contract development and manufacturing organization (
Up to one in four infants experience colic, often manifesting in excessive crying and fussing. In a new study, children with colic consuming Chr. Hansen’s BB-12® probiotic strain Bifidobacterium, have experienced less excessive crying and fussing, accompanied by increased sleep time. The mechanism by which Bifidobacterium, BB-12® exerts a beneficial effect on the study group is expected to be the
Chr. Hansen is joining forces with global agricultural solutions provider UPL in a unique partnership to strengthen the existing portfolio of microbial products and provide farmers with sustainable choices beyond conventional agricultural products.
Biological solutions are becoming more and more in demand as the agriculture industry faces challenges such as the growing resistance to chemica
Progressing on the 2025 Strategy priorities, outlook for the new financial year is 5-8% organic growth
A year of transition
Statement by CEO Mauricio Graber: “Our performance of 7% organic growth and our EBIT margin b.s.i. of 27.7% both ended at the upper end of our initial outlook range for the full year. Free cash flow before acquisitions and special items ended at EUR 196 million and
Introducing a new portfolio of stable live probiotics for use in pet foods and supplements, empowering every pet’s life stage with good bacteria
Pet food and supplements brands face many challenges. They need to continuously keep up with the pace of innovation and expectations of a new generation of millennial pet parents, who look for natural, safe, effective and sustainable solutions. Today
New study published in “Nutrients” shows safety and tolerability of infant formula containing the five most abundant Human Milk Oligosaccharides in natural concentrations
Human Milk Oligosaccharides (HMOs) are the third most abundant components exclusively found in human breast milk. They are known to provide benefits to infants by supporting the immune system, promoting growth of beneficial gu
Chr. Hansen A/S has reached a settlement with Glycom A/S of several patent disputes, including litigations in Denmark, relating to the production of Human Milk Oligosaccharides (HMOs)
The disputes were inherited by Chr. Hansen through the acquisition of Jennewein Biotechnologie GmbH in 2020.
As part of the settlement of the patent disputes, Chr. Hansen and Glycom have agreed on royalty-
On track to deliver ambition for the year, outlook for 2020/21 unchanged
Q3 2020/21 organic sales growth was 4%, equally split between volume/mix and price. The Q3 organic growth was impacted by a reduced contribution from EUR-based pricing compared to the first half, and a higher comparable, as Q3 last year was positively impacted by COVID-19 related customer inventory build-up. YTD organic g
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Boege Allé 10-12
DK-2970 Hoersholm
Denmark